In honor of National Pancreatic Cancer Awareness Month (November) and World Pancreatic Cancer Day (Nov. 16th), we’ve compiled some important statistics about the disease—and how we plan to combat it.
Pancreatic cancer is one of the deadliest forms of cancer. According to the American Cancer Society, more than 53,000 new cases of pancreatic cancer will be diagnosed by the end of 2017. Even with the best treatments currently available, 43,000 people will die from the disease. About 71 percent of pancreatic cancer patients die within one year after they are diagnosed, and the life expectancy of those with pancreatic cancer is a few years at best. The mortality rate is 91%.
These statistics make pancreatic cancer one of the deadliest forms of cancer. It’s not just cancer – it’s an emergency. New end effective treatments for the disease must be developed. Pancreatic cancer patients and their families deserve better. In fact, they demand better. They demand a new approach.
Currently, PharmaCyte Biotech is in the late stages of preparing an Investigational New Drug application (IND) to be submitted to the U.S. FDA for the novel treatment for a particular segment of those diagnosed with pancreatic cancer. Acceptance of the IND by the FDA will permit PharmaCyte to begin its very important clinical trial.
The patients to be treated in the trial will be those diagnosed with locally advanced, non-metastatic, inoperable disease who have already been treated for four to six months with the combination of Abraxane® plus gemcitabine—currently the standard of care for pancreatic cancer—and their tumors must be stable or progressing only locally (not yet metastasized).
PharmaCyte’s treatment will consist of implanting encapsulated living cells capable of converting the cancer prodrug ifosfamide into its “cancer-killing” form. The patients will then be administered ifosfamide at one-third the normal dose. Earlier clinical trials have shown this treatment to be both effective against the cancer and safe for the patients undergoing treatment – with no treatment related side effects.
PharmaCyte’s treatment will be compared with a commonly used treatment for the care of pancreatic cancer patients with the same disease profile. If our therapy is significantly superior to the comparator treatment in terms of overall survival and safety, the FDA may grant our therapy marketing approval.
The gains we are making with our pancreatic cancer therapy are one more reason for pancreatic cancer patients and their families to #WageHope.